53 news items
Page 3 of 3
kdp3zky06vvzy8qzjnb8ds
BMY
11 Apr 24
been targeting a price range from $40.0 to $70.0 for Bristol-Myers Squibb over the last 3 months.
Analyzing Volume & Open Interest
7s5swpg4rkxn2gl8duhnkzjqv2zi
BMY
8 Apr 24
for Krazati in combination with cetuximab as a targeted treatment option for patients with previously treated KRASG12C-mutated locally advanced or metastatic
8yz vp751yt5ar732ephtv0h3jswuea6cioq2
BMY
8 Apr 24
with KRAS-mutated cancers, who continue to need new, targeted treatment options," said Anne Kerber, senior vice president, head of late clinical
c33v 1h7glu
BMY
8 Apr 24
, such as those with KRAS-mutated cancers, who continue to need new, targeted treatment options," said Anne Kerber, senior vice president, head of late
6rzca9z2plope2kdf3u3r4pcus2scyz j8t
BMY
6 Apr 24
and improving quality of life. Leveraging genetics, biomarkers and predictive sciences, we target key pathways involved in the initiation and progression
1lvteg
BMY
6 Apr 24
with the goal of modifying disease and improving quality of life. Leveraging genetics, biomarkers and predictive sciences, we target key pathways involved
63cx1gex
BMY
2 Apr 24
clinical trial participants in the U.S. with 26% vs. target 20%; achieved 23% ethnically diverse patients, exceeding goal of 18%. Moving forward, BMS
3zpcnmd40o ybv
BMY
ZLAB
1 Apr 24
profile.
The FDA granted accelerated approval for Krazati as a targeted treatment for patients with KRASG12C-mutated locally advanced
3q4nm1gw50uf9qcsqb1xdxtgxdnrvkpb0yruojolo4q0q67tamz4qwhyl0
BMY
CATX
LNTH
28 Mar 24
designed VMT01 to target and deliver 212Pb to tumor sites expressing melanocortin 1 receptor ("MC1R"), a protein that is overexpressed
2rjdyv6at
ATNM
AZN
BMY
27 Mar 24
) to initiate a clinical trial for Iomab-ACT, a revolutionary targeted radiotherapy conditioning agent. This pioneering study, aimed at enhancing
jsrw11g1m7widui7hlrh7u8j3drcdapd87ol0h
ARGX
ATNM
AZN
26 Mar 24
emitters like Actinium-225 (Ac-225), are gaining prominence for their targeted approach to cancer treatment. Amid this innovative surge
5un09nswt9napddaii4vg3punf02fvbo
ATNM
AZN
BMY
25 Mar 24
, a first-in-class small molecule corrector, targets the fundamental cause of ADPKD, offering a beacon of hope for those suffering from
apg5jexrt 5q4wju7fzpg4x19m3gxfidkh0co4oc9829twokfbpxg9qotjq
ARGX
ATNM
AZN
22 Mar 24
(NYSE:ATNM) develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies